Year All 2026 2025 2024 2023 2022 2021 2020 2019 Nov 06, 2026 Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2026 Financial Results Nov 05, 2026 Aligos Therapeutics Presents Positive Data at The Liver Meeting® 2026 Oct 05, 2026 Aligos Therapeutics Announces Five Abstracts Accepted for Presentation at The Liver Meeting® 2026 Sep 02, 2026 Aligos Therapeutics to Present at the Cantor Global Healthcare Conference Aug 12, 2026 Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China Aug 06, 2026 Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results Jul 30, 2026 Aligos Therapeutics to Announce 2nd Quarter 2026 Financial Results on August 6, 2026 Jul 13, 2026 Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection Jul 06, 2026 Aligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection May 27, 2026 Aligos Therapeutics Presents Positive Data at the EASL Congress 2026
Nov 06, 2026 Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2026 Financial Results
Oct 05, 2026 Aligos Therapeutics Announces Five Abstracts Accepted for Presentation at The Liver Meeting® 2026
Aug 12, 2026 Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China
Aug 06, 2026 Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results
Jul 13, 2026 Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection
Jul 06, 2026 Aligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection
